[MoPe10.2P08] Persistently High HIV Incidence Rates Among Injection Drug Users In Vancouver, Canada (1992-2003)

3rd International AIDS Society Conference on HIV Pathogenesis and Treatment

Rio de Janeiro - July 24 - 27, 2005

PERSISTENTLY HIGH HIV INCIDENCE RATES AMONG INJECTION DRUG USERS IN VANCOUVER, CANADA (1992-2003)

IAS Conf HIV Pathog Treat 2005 Jul 24-27;3rd: Abstract No. MoPe10.2P08

Tyndall M.¹, Kerr T.¹, Wood E.¹, Lai C.¹, Shannon K.¹, Cook D.², Montaner J.¹
¹BC Centre for Excellence in HIV/AIDS, Vancouver, Canada, ²BC Centre for Disease Control, Vancouver, Canada

INTRODUCTION: Vancouver experienced an explosive outbreak of HIV infection among injection drug users living in a densely populated urban neighborhood during the mid-1990s. This prompted a number of responses including greater police enforcement, harm reduction strategies and improved health care services. In order to assess the impact of these interventions we estimated the HIV incidence rates between 1992 and 2003 using three large prospective cohort studies that are operating in the community.

METHODS: The VIDUS (n=1,588) study began enrolment in 1996 and follows injection drug users. The CHASE Project (n=3,614) began in January 2003 and is designed to follow a representative sample of community residents. The SEOSI cohort (n=1,015) is designed to evaluate the supervised injection site that opened in September 2003. Using names, dates of birth and Health Card numbers, linkages were made with a centralized provincial HIV database (BCCDC) in order to determine the rates of infection.

RESULTS: This analysis includes 2,802 participants who had at least one HIV test recorded between 1992 and 2003. The incidence calculations were based on 479 HIV seroconverters. During this period the cumulative HIV prevalence increased from 1% to 35%. The incidence rates were estimated to be 0.2 per 100 person-year in 1992, 0.8% (1993), 1.6% (1994), 2.3% (1995), 2.2% (1996),1.9% (1997), 1.6% (1998), 1.4% (1999), 2.1% (2000), 1.7% (2001), 1.3% (2002), and 1.3% (2003).

CONCLUSIONS: The risk of HIV transmission among a community with endemic rates of injection drug use has been consistently high over the past decade with peaks in 1995 and 2000. Longitudinal data is critical in order to assess the impact of prevention and harm reduction efforts, which in this community appear to be falling short.

Download PDF of this abstract.

050724
Prevention | MoPe10.2P08 | Mark Tyndall
10.2 71 10.2 HIV incidence measurement

Copyright © 2005 - International AIDS Society (IAS). All information and content relating to the abstracts from the 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.